159938 医药
已收盘 12-29 15:00:00
资讯
新帖
简况
12月29日三博脑科涨7.21%，银河医药混合A基金重仓该股
证券之星 · 10分钟前
12月29日三博脑科涨7.21%，银河医药混合A基金重仓该股
申万宏源：首次覆盖晶泰控股(02228)给予“买入”评级 从医药到AI4S全面布局
智通财经网 · 14:21
申万宏源：首次覆盖晶泰控股(02228)给予“买入”评级 从医药到AI4S全面布局
每周股票复盘：复星医药（600196）拟控股投资绿谷医药
证券之星 · 12-28 01:38
每周股票复盘：复星医药（600196）拟控股投资绿谷医药
航天发展：公司不存在太空医药研发部门
证券之星 · 12-26 20:49
航天发展：公司不存在太空医药研发部门
新股消息 | 海纳医药拟港股上市 中国证监会要求补充说明募集资金具体用途
智通财经 · 12-26 20:44
新股消息 | 海纳医药拟港股上市 中国证监会要求补充说明募集资金具体用途
欧康医药（920230）披露股权激励计划限制性股票解除限售公告，12月26日股价下跌1.03%
证券之星 · 12-26 17:49
欧康医药（920230）披露股权激励计划限制性股票解除限售公告，12月26日股价下跌1.03%
森萱医药（920946）披露子公司涉及诉讼结果公告，12月26日股价下跌0.65%
证券之星 · 12-26 17:46
森萱医药（920946）披露子公司涉及诉讼结果公告，12月26日股价下跌0.65%
健康之路附属拟出售福建健宸医药有限公司51%的股权
新浪港股 · 12-26
健康之路附属拟出售福建健宸医药有限公司51%的股权
券商“抢人战”一角：国盛证券医药、计算机、传媒等多行业分析师密集被挖，分仓佣金连降
蓝鲸财经 · 12-25
券商“抢人战”一角：国盛证券医药、计算机、传媒等多行业分析师密集被挖，分仓佣金连降
国泰海通｜医药：第六批耗材国采降幅预期温和，有望加速国产厂商放量
国泰君安证券研究 · 12-25
国泰海通｜医药：第六批耗材国采降幅预期温和，有望加速国产厂商放量
两名研究大咖去向揭秘！原国盛证券医药首席分析师张金洋、原招商证券银行业首席分析师王先爽加盟国联民生
新浪证券 · 12-25
两名研究大咖去向揭秘！原国盛证券医药首席分析师张金洋、原招商证券银行业首席分析师王先爽加盟国联民生
盘龙药业：暂无与拜耳医药等企业项目合作
证券之星 · 12-25
盘龙药业：暂无与拜耳医药等企业项目合作
国信证券：美国医药供应链新规出台 关注CXO板块投资机会
智通财经 · 12-25
国信证券：美国医药供应链新规出台 关注CXO板块投资机会
泓博医药最新公告：股东泓博智源（香港）医药技术有限公司拟询价转让697.93万股股份
证券之星 · 12-24
泓博医药最新公告：股东泓博智源（香港）医药技术有限公司拟询价转让697.93万股股份
健康之路(02587)附属拟出售福建健宸医药有限公司51%的股权
智通财经 · 12-24
健康之路(02587)附属拟出售福建健宸医药有限公司51%的股权
新股消息 | 新济医药递表港交所
智通财经 · 12-24
新股消息 | 新济医药递表港交所
医药巨头，突然暴涨
中国基金报 · 12-24
医药巨头，突然暴涨
医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海
MedTrend医趋势 · 12-23
医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海
鹭燕医药：海南封关将助力医药产品跨境流通
证券之星 · 12-23
鹭燕医药：海南封关将助力医药产品跨境流通
创金合信医药消费股票A基金经理变动：刘迪不再担任该基金基金经理
证券之星 · 12-23
创金合信医药消费股票A基金经理变动：刘迪不再担任该基金基金经理
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.657,"timestamp":1766991789000,"preClose":0.663,"halted":0,"volume":34021462,"delay":0,"changeRate":-0.009,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.006,"latestTime":"12-29 15:00:00","open":0.661,"high":0.663,"low":0.655,"amount":22383100,"amplitude":0.0121,"askPrice":0.657,"askSize":7151,"bidPrice":0.656,"bidSize":157,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767058200000},"marketStatusCode":5,"adr":0,"adjPreClose":0.663,"symbolType":"fund","openAndCloseTimeList":[[1766971800000,1766979000000],[1766984400000,1766991600000]],"highLimit":0.729,"lowLimit":0.597,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.220197,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2595207292","title":"12月29日三博脑科涨7.21%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595207292","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595207292?lang=zh_cn&edition=full","pubTime":"2025-12-29 15:38","pubTimestamp":1766993939,"startTime":"0","endTime":"0","summary":"证券之星消息，12月29日三博脑科涨7.21%，收盘报60.38元，换手率12.78%，成交量20.57万手，成交额12.34亿元。重仓三博脑科的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为5.03亿元，最新净值0.5598，较上一交易日下跌0.6%，近一年上涨11.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900014580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK0236","BK1515","301293","BK1574","BK1161","159938"],"gpt_icon":0},{"id":"2595120773","title":"申万宏源：首次覆盖晶泰控股(02228)给予“买入”评级 从医药到AI4S全面布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2595120773","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595120773?lang=zh_cn&edition=full","pubTime":"2025-12-29 14:21","pubTimestamp":1766989266,"startTime":"0","endTime":"0","summary":"底层技术逻辑能够迁移至新材料等领域，仅考虑AI4S在药研和材料研发两大领域，远期AI服务空间可达近500亿美元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251229/20251229142140_13794.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251229/20251229142140_13794.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159938","02228","09939","000166"],"gpt_icon":0},{"id":"2594024193","title":"每周股票复盘：复星医药（600196）拟控股投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2594024193","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594024193?lang=zh_cn&edition=full","pubTime":"2025-12-28 01:38","pubTimestamp":1766857092,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，复星医药报收于26.89元，较上周的27.27元下跌1.39%。本周关注点公司公告汇总：复星医药拟出资14.12亿元控股投资绿谷医药，标的公司主要产品甘露特钠胶囊已暂停生产和销售。公司公告汇总复星医药就控股投资绿谷医药事项回复上海证券交易所监管工作函。本次变动涉及吴中引导基金中心向吴中引导基金公司转让6,000万元基金份额，以及宁波复瀛向复星医药产业划转34,000万元基金份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0096","BK0028","BK1515","BK0196","BK0012","BK0060","BK0183","BK0175","BK0188","BK1191","09939","02196","BK1574","BK0187","159938","600196","BK1161","BK0239"],"gpt_icon":0},{"id":"2594329989","title":"航天发展：公司不存在太空医药研发部门","url":"https://stock-news.laohu8.com/highlight/detail?id=2594329989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594329989?lang=zh_cn&edition=full","pubTime":"2025-12-26 20:49","pubTimestamp":1766753348,"startTime":"0","endTime":"0","summary":"证券之星消息，航天发展(000547)12月26日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好；太空特殊的环境，可能对医药卫生的研发有独特的优势，比如“太空病房”“太空手术”“太空临床试验”等，这也是商业航天一个可能的应用领域，公司是否有太空医药研发或者卫生研究的部门或者合作伙伴呢？祝好航天发展回复：投资者您好！公司目前不存在问题所述太空医药研发、卫生研究的部门或合作伙伴。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600033177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1515","000547","BK1161","BK1574","BK0214","09939","BK0037","159938","BK0024"],"gpt_icon":0},{"id":"2594967092","title":"新股消息 | 海纳医药拟港股上市 中国证监会要求补充说明募集资金具体用途","url":"https://stock-news.laohu8.com/highlight/detail?id=2594967092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594967092?lang=zh_cn&edition=full","pubTime":"2025-12-26 20:44","pubTimestamp":1766753085,"startTime":"0","endTime":"0","summary":"中国证监会国际司公示19家企业补充材料要求，其中，要求海纳医药补充说明募集资金具体用途，境内外用途占比情况等事项。据悉，海纳医药已于2025年11月7日递表港交所，中金公司为独家保荐人。根据同一来源，海纳医药于同期提交的临床试验及上市许可申请总数方面亦排名第二。截至2022年、2023年及2024年12月31日以及2025年6月30日，海纳医药分别有242个、331个、383 个及398个正在进行的CXO项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2594878298","title":"欧康医药（920230）披露股权激励计划限制性股票解除限售公告，12月26日股价下跌1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594878298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594878298?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:49","pubTimestamp":1766742554,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，欧康医药报收于12.43元，较前一交易日下跌1.03%，最新总市值为12.52亿元。公司近日发布公告称，成都欧康医药股份有限公司本次解除限售的限制性股票数量为508,209股，占公司总股本的0.5046%，可交易时间为2025年12月30日。本次解除限售涉及34名股东，其中核心员工共30人，董事及高管4人。解除后，公司有限售条件股份合计为53,500,272股，无限售条件股份为47,217,223股，总股本保持不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600026005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","09939","BK1161","159938"],"gpt_icon":0},{"id":"2594861298","title":"森萱医药（920946）披露子公司涉及诉讼结果公告，12月26日股价下跌0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594861298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594861298?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:46","pubTimestamp":1766742364,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，森萱医药报收于10.76元，较前一交易日下跌0.65%，最新总市值为45.94亿元。该股当日开盘10.8元，最高10.9元，最低10.75元，成交额达2948.74万元，换手率为0.64%。公告显示，该事件未对公司财务造成重大不利影响，宁夏森萱已于2024年7月恢复正常生产经营，判决不会导致公司触及重大违法强制退市情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600025843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","09939","BK1574","159938"],"gpt_icon":0},{"id":"2594506992","title":"健康之路附属拟出售福建健宸医药有限公司51%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2594506992","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594506992?lang=zh_cn&edition=full","pubTime":"2025-12-26 09:34","pubTimestamp":1766712840,"startTime":"0","endTime":"0","summary":" 健康之路公布，于2025年12月24日，公司的全资附属公司浙江健康之路科技集团有限公司拟向肖靖女士出售福建健宸医药有限公司51%的股权，总代价为人民币167.79万元。出售公司的主要活动为批发药品、经营第三类医疗器械、销售第一类医疗器械及销售第二类医疗器械。 出售公司因于2023年末流感疫情爆发期间囤积奥司他韦而取得收入暂时性增长。随着疫情的消退，出售公司作为单一产品存货的药品批发商的局限性变得显而易见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-12-26/doc-inheautp8150724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1219","09939","159938","BK1515","02587"],"gpt_icon":0},{"id":"2594023715","title":"券商“抢人战”一角：国盛证券医药、计算机、传媒等多行业分析师密集被挖，分仓佣金连降","url":"https://stock-news.laohu8.com/highlight/detail?id=2594023715","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594023715?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:39","pubTimestamp":1766673562,"startTime":"0","endTime":"0","summary":"Wind数据显示，今年上半年，国盛证券分仓佣金收入0.95亿元，同比下滑28.35%，行业排名21。年末“离职潮”发酵记者通过中国证券业协会从业人员信息系统查询发现，12月，国盛证券研究所已有多名覆盖医药、计算机、传媒等行业的分析师处于“离职”状态。伴随卖方研究整体发展承压，国盛证券研究所佣金收入的下滑趋势较为显著。去年全年分仓佣金收入2.39亿元，较上一年度下滑25.55%，行业排名19。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766662779815085676","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0276","BK1574","002670","09939","01981","BK1515","BK1128","159998","159938","BK1161","BK0052"],"gpt_icon":0},{"id":"2594237258","title":"国泰海通｜医药：第六批耗材国采降幅预期温和，有望加速国产厂商放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2594237258","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594237258?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:50","pubTimestamp":1766667000,"startTime":"0","endTime":"0","summary":"手术量不及预期，集采执行时间不及预期，产品价格波动风险等。报告来源以上内容节选自国泰海通证券已发布的证券研究报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650535612&idx=5&sn=0bce018bdef48a95ca59f91b7af68c19&chksm=899b0656d8f53b3aae98eedac45407c008d09bc08b8d326656c99ad01a980ac6ea1e3d0c56c7&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","BK1147","BK0012","09939","BK0188","02611","BK0201","BK0276","BK0183","BK1515","601211","BK0028","159938","BK0184","BK1564","BK1574"],"gpt_icon":0},{"id":"2594233030","title":"两名研究大咖去向揭秘！原国盛证券医药首席分析师张金洋、原招商证券银行业首席分析师王先爽加盟国联民生","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233030","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594233030?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:58","pubTimestamp":1766653080,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月25日消息，据悉，近期国联民生研究所又有两员大将加盟——素有“创新药骑手”之称的原国盛证券医药首席分析师张金洋，携核心团队正式入职，出任研究所副总经理兼医药行业首席分析师。同时，银行业研究新晋实力派“卷王”、原招商证券银行业首席分析师王先爽，也率团队强势加入，担任所长助理、银行首席分析师兼货币金融研究院院长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-25/doc-inhczaki8965976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1515","BK0183","01456","BK1147","BK0052","BK0010","BK1574","BK0012","BK0276","BK0028","09939","06099","600999","BK1564","002670","601456","BK0188","159938"],"gpt_icon":0},{"id":"2594280283","title":"盘龙药业：暂无与拜耳医药等企业项目合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2594280283","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594280283?lang=zh_cn&edition=full","pubTime":"2025-12-25 15:31","pubTimestamp":1766647881,"startTime":"0","endTime":"0","summary":"证券之星消息，盘龙药业(002864)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司与拜耳医药、罗氏医药、辉瑞制药等企业是否有项目合作？盘龙药业回复：尊敬的投资者您好！公司与拜耳医药、罗氏医药、辉瑞制药等企业暂无项目合作。 感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500016993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK1515","BK1574","BK1161","BK0239","002864"],"gpt_icon":0},{"id":"2594286909","title":"国信证券：美国医药供应链新规出台 关注CXO板块投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2594286909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594286909?lang=zh_cn&edition=full","pubTime":"2025-12-25 09:40","pubTimestamp":1766626821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，美国国会近日通过2026财年国防授权法案，其中纳入修订版《生物安全法案》相关条款，中国创新药产业长期竞争力仍受看好。建议关注CXO板块，并留意创新药海外临床进展。国信证券主要观点如下：《生物安全法案》获参、众议院通过，关注CXO板块投资机会美国时间12月17日，美国参议院以77票赞成、20票反对的表决结果，通过2026财年国防授权法案。法案后续将提交白宫，待美国总统签署生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","BK1515","BK1574","CXO","09939","BK0276","159938","002736","BK1161","BK0183"],"gpt_icon":0},{"id":"2593347915","title":"泓博医药最新公告：股东泓博智源（香港）医药技术有限公司拟询价转让697.93万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593347915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593347915?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:00","pubTimestamp":1766574023,"startTime":"0","endTime":"0","summary":"泓博医药(301230.SZ)公告称，公司持股5%以上的股东泓博智源（香港）医药技术有限公司计划通过询价转让方式，转让其持有的697.93万股公司股份，占公司总股本的5.00%，占剔除公司回购专用账户后的总股本的5.07%。转让原因为自身资金需求。本次询价转让不通过集中竞价交易或大宗交易方式进行，受让方通过询价转让受让的股份在受让后6个月内不得转让。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400031582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1161","09939","301230","159938","BK1515","BK1574"],"gpt_icon":0},{"id":"2593047310","title":"健康之路(02587)附属拟出售福建健宸医药有限公司51%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2593047310","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593047310?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:30","pubTimestamp":1766568608,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康之路 公布，于2025年12月24日，公司的全资附属公司浙江健康之路科技集团有限公司拟向肖靖女士出售福建健宸医药有限公司51%的股权，总代价为人民币167.79万元。出售公司因于2023年末流感疫情爆发期间囤积奥司他韦而取得收入暂时性增长。随着疫情的消退，出售公司作为单一产品存货的药品批发商的局限性变得显而易见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","02587","BK1161","BK1574","BK1219","09939","BK1515"],"gpt_icon":0},{"id":"2593422587","title":"新股消息 | 新济医药递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422587?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:13","pubTimestamp":1766560418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月24日披露，广州新济医药股份有限公司向港交所主板递交上市申请书，国泰海通为其独家保荐人。新济医药的首项核心产品盐酸右美托咪定微针贴剂乃为儿童患者及成人患者的术前镇静而开发。截至2025年12月18日，盐酸右美托咪定微针贴剂已于中国进入用于儿童患者的IIa期临床试验。NMPA已批准开始用于成人患者的II期临床试验，而相关临床试验预计于2026年第一季开始。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","BK1161","159938","HEXmain"],"gpt_icon":0},{"id":"2593444150","title":"医药巨头，突然暴涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2593444150","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593444150?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:19","pubTimestamp":1766535577,"startTime":"0","endTime":"0","summary":"【导读】英伟达大涨超3%，诺和诺德暴涨7.3%，铜价超12000美元/盎司中国基金报记者储是隔夜美股市场，标普500指数创新高。英伟达领涨科技股，市值重回4.6万亿美元。继黄金、白银后，铜价也创下新高。标普500指数创新高美东时间12月23日（周二），美股盘中持续走强，三大指数均收涨，其中标普500指数收于新高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512243600135425.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600135425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1515","09939","159938","BK1161"],"gpt_icon":0},{"id":"2593869497","title":"医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2593869497","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593869497?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:44","pubTimestamp":1766490240,"startTime":"0","endTime":"0","summary":"盐野义方面表示，预计该交易将于2026年4月1日或之后完成交割，交易完成后每年将为公司新增约7亿美元的全球销售额。根据官方披露，盐野义将以25亿美元的一次性付款方式收购Radicava相关业务，同时约定在“特定条件”下支付潜在的未来特许权使用费。交易交割后，Radicava业务单元将成为盐野义的全资子公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-12-23/doc-inhcuyui5237827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK4231","BK1574","BK4080","ADC","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2593462888","title":"鹭燕医药：海南封关将助力医药产品跨境流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2593462888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593462888?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:07","pubTimestamp":1766473639,"startTime":"0","endTime":"0","summary":"公司于2023年9月对海南鹭燕增资，将海南鹭燕的注册资本由3500万元增至1亿元，用于满足海南鹭燕经营发展及“鹭燕医药海南总部基地项目”建设需要。海南封关，将为公司医药产品跨境流通业务提供助力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300018908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK1574","BK1161","002788","BK1515","BK0250"],"gpt_icon":0},{"id":"2593452284","title":"创金合信医药消费股票A基金经理变动：刘迪不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593452284?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:31","pubTimestamp":1766453489,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月23日，创金合信医药消费股票（010585）发布公告，刘迪不再担任该基金基金经理，离任日期为2025年12月23日，变更后创金合信医药消费股票（010585）的基金经理为毛丁丁,皮劲松。截止2025年12月22日，创金合信医药消费股票净值为0.4562，较上一日下跌0.24%，近一年下跌7.78%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300007577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09939","159938","BK1161","BK1515"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766994489817,"stockEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0192},{"period":"3month","weight":-0.0893},{"period":"6month","weight":0.0507},{"period":"1year","weight":0.0694},{"period":"ytd","weight":0.0833}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}